Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Previous Page Next Page


Entrectinib (RDX-101, NMS-P626), a first-generation TRK inhibitor, is a small molecule multi-kinase inhibitor [1-3]. Entrectinib is orally available, with a plasma half-life of 20–22 hours, allowing for a once daily, continuous dosing regimen (600 mg daily was identified as the maximum tolerated dose in adults in phase 1/2 trials [3]).

In 2017, entrectinib was granted breakthrough therapy and orphan drug designation by the US FDA [4]. In addition, the EMA granted entrectinib a priority medicines designation in the same year [5].  In June 2019, entrectinib was approved in Japan for the treatment of adult and paediatric patients NTRK fusion-positive, advanced recurrent solid tumours [6]. In August 2019, entrectinib was approved for the treatment of adults and pediatric patients ≥12 years of age and older with solid tumours that have a NTRK gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory standard therapy [7].


  1. Ardini E, Menichincheri M, Banfi P et al. Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications. Mol Cancer Ther 2016; 15: 628-639.
  2. Liu D, Offin M, Harnicar S et al. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag 2018; 14: 1247-1252.
  3. Drilon A, Siena S, Ou SI et al. Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). Cancer Discov 2017; 7: 400-409.
  4. Drugs.com. Entrectinib Approval Status. 2019.
  5. eCancer News. EMA issues PRIME designation for entrectinib in NTRK fusion solid tumours. 2017.
  6. Roche. Media release. 2019. https://www.roche.com/media/releases/med-cor-2019-06-18.htm (accessed 24 June 2019).
  7. Food & Drug Administration. 2019. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc (accessed 20 August 2019).

Clinical Data

The efficacy and safety of entrectinib has been studied in phase 1/2 clinical trials.

Read more

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.